Referred to the Committee on Energy and Commerce, and in addition to the Committee on Oversight and Government Reform, for a period to be subsequently determined by the Speaker, i…
The bill, "Doctor Knows Best Act of 2025," prohibits group health plans, health insurance issuers, and Federal health care programs from imposing prior authorization, utilization management (including step therapy/fail-first), or medical necessity reviews for any covered item or service. The private-insurer prohibition applies to plan years beginning on or after January 1, 2026; the Federal program prohibition begins January 1, 2026.
Access speed and clinician autonomy vs retaining cost controls
Relative to its intended legislative type, this bill is a clear and direct substantive policy change that decisively prohibits prior authorization, utilization management, and medical necessity reviews across specified private and Federal health coverage.
The bill, "Doctor Knows Best Act of 2025," prohibits group health plans, health insurance issuers, and Federal health care programs from imposing prior authorization, utilization management (including step therapy/fail-first), or medical necessity reviews for any covered item or service.
The private-insurer prohibition applies to plan years beginning on or after January 1, 2026; the Federal program prohibition begins January 1, 2026.
No exceptions or alternative review processes are specified in the text.
Broad, expensive prohibition lacking carve‑outs or phased implementation; significant opposition from payers and budget hawks likely.
Relative to its intended legislative type, this bill is a clear and direct substantive policy change that decisively prohibits prior authorization, utilization management, and medical necessity reviews across specified private and Federal health coverage. It identifies statutory insertion points and effective dates but omits many elements typically expected for a large operational change.
Access speed and clinician autonomy vs retaining cost controls
These are examples from the analysis, not a ranked list of the most-affected groups.
Access speed and clinician autonomy vs retaining cost controls
Likely broadly supportive because the bill removes administrative barriers to care and restores clinician decision-making.
Support would be tempered by concerns about cost increases and impacts on vulnerable populations.
Supporters would urge safeguards to prevent price shocks or reduced access to essential services.
Views are mixed: the bill removes real administrative barriers but eliminates widely used cost and quality controls.
Centrist evaluators would seek targeted, evidence-based exceptions, phase-in, and fiscal analysis before endorsing.
They favor compromise rather than a blanket ban.
Likely strongly opposed.
The bill removes insurer flexibility and federal program controls that limit overuse and contain costs.
Conservatives would emphasize market discipline, fiscal impacts, and federal overreach into plan design.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Broad, expensive prohibition lacking carve‑outs or phased implementation; significant opposition from payers and budget hawks likely.
The bill has not accumulated any surfaced votes yet.
Access speed and clinician autonomy vs retaining cost controls
Broad, expensive prohibition lacking carve‑outs or phased implementation; significant opposition from payers and budget hawks likely.
Relative to its intended legislative type, this bill is a clear and direct substantive policy change that decisively prohibits prior authorization, utilization management, and medical necessity reviews across specified…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.